There is substantial evidence to support the pivotal roles of MIF and DDT in cancer progression and highlight their potential as promising and broadly applicable targets in oncology, arguing for the need for expanded research and clinical trials to establish their efficacy in cancer therapy. The gene discussed is MIF; the disease is cancer.